Facebook Instagram Twitter RSS Feed PodBean Back to top on side

Changes in urine autofluorescence in ovarian cancer patients

In: NEOPLASMA, vol. 61, no. 6
A. Birkova - A. Gresova - Z. Steffekova - V. Kraus - A. Ostro - R. Toth - M. Marekova
Detaily:
Rok, strany: 2014, 724 - 731
O článku:
Ovarian cancer is the type of cancer with the highest mortality rate among gynaecologic malignancies. Due to lack of screening tools, this disease is mainly diagnosed at a progressed stage, when it is too late to adequate therapy. Despite many attempts, enough sensitive and specific biomarker was not still uncovered. Fluorescence spectroscopy has proven to be a useful diagnostic tool with high efficiency. Fluorescence detection has three major advantages over other light-based investigation methods: high sensitivity, high speed, and reliability. Biological materials consist of a number of intrinsic fluorescent compounds –autofluorophores, which are associated with cardinal metabolic pathways. It is well known, that cancerous tissue metabolism is altered compared to healthy one, what influence also intrinsic fluorophores composition of bodily fluids. Urine is one of the biological fluids that could be obtained most easily and displays a blue – green fluorescence that can change in case of pathological process. Analysis of urine autofluorescence is non invasive and simple technique. Using fluorescent spectroscopy, ovarian cancer patients and healthy control group were discerned with high significance, so we predict that fluorescence analysis of urine could be a potential means of ovarian cancer screening. Keywords: fluorescence, cancer screening, urine, ovarian cancer
Ako citovať:
ISO 690:
Birkova, A., Gresova, A., Steffekova, Z., Kraus, V., Ostro, A., Toth, R., Marekova, M. 2014. Changes in urine autofluorescence in ovarian cancer patients. In NEOPLASMA, vol. 61, no.6, pp. 724-731. 0028-2685.

APA:
Birkova, A., Gresova, A., Steffekova, Z., Kraus, V., Ostro, A., Toth, R., Marekova, M. (2014). Changes in urine autofluorescence in ovarian cancer patients. NEOPLASMA, 61(6), 724-731. 0028-2685.